90 related articles for article (PubMed ID: 36100970)
1. Current therapeutic options for glioblastoma and future perspectives.
Aquilanti E; Wen PY
Expert Opin Pharmacother; 2022 Oct; 23(14):1629-1640. PubMed ID: 36100970
[TBL] [Abstract][Full Text] [Related]
2. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Weller M; Cloughesy T; Perry JR; Wick W
Neuro Oncol; 2013 Jan; 15(1):4-27. PubMed ID: 23136223
[TBL] [Abstract][Full Text] [Related]
3. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Ellingson BM; Wen PY; Chang SM; van den Bent M; Vogelbaum MA; Li G; Li S; Kim J; Youssef G; Wick W; Lassman AB; Gilbert MR; de Groot JF; Weller M; Galanis E; Cloughesy TF
Neuro Oncol; 2023 Jun; 25(6):1017-1028. PubMed ID: 36617262
[TBL] [Abstract][Full Text] [Related]
4. The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
Harari-Turquie M; Moturi KR; Horton DD; Rabinowitz I
J Investig Med High Impact Case Rep; 2023; 11():23247096231193266. PubMed ID: 37596951
[TBL] [Abstract][Full Text] [Related]
5. Investigational treatment strategies in glioblastoma: progress made and barriers to success.
Nelson TA; Dietrich J
Expert Opin Investig Drugs; 2023; 32(10):921-930. PubMed ID: 37796104
[TBL] [Abstract][Full Text] [Related]
6. State of the art and perspectives in the treatment of glioblastoma.
Grimm SA; Chamberlain MC
CNS Oncol; 2012 Sep; 1(1):49-70. PubMed ID: 25054300
[TBL] [Abstract][Full Text] [Related]
7. Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Waqar M; Trifiletti DM; McBain C; O'Connor J; Coope DJ; Akkari L; Quinones-Hinojosa A; Borst GR
Curr Oncol Rep; 2022 Mar; 24(3):311-324. PubMed ID: 35119629
[TBL] [Abstract][Full Text] [Related]
8. Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
Ziani-Zeryouh A; Wouters R; Thirion G; Vandenbrande K; Vankerckhoven A; Berckmans Y; Bevers S; Verbeeck J; De Keersmaecker K; Coosemans A; Riva M
Methods Cell Biol; 2024; 183():381-397. PubMed ID: 38548420
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.
Birzu C; French P; Caccese M; Cerretti G; Idbaih A; Zagonel V; Lombardi G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375286
[TBL] [Abstract][Full Text] [Related]
10. Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.
Funakoshi Y; Hata N; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Takigawa K; Mizoguchi M
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33339404
[TBL] [Abstract][Full Text] [Related]
11. Current and investigational drug strategies for glioblastoma.
Ajaz M; Jefferies S; Brazil L; Watts C; Chalmers A
Clin Oncol (R Coll Radiol); 2014 Jul; 26(7):419-30. PubMed ID: 24768122
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY; Weller M; Lee EQ; Alexander BM; Barnholtz-Sloan JS; Barthel FP; Batchelor TT; Bindra RS; Chang SM; Chiocca EA; Cloughesy TF; DeGroot JF; Galanis E; Gilbert MR; Hegi ME; Horbinski C; Huang RY; Lassman AB; Le Rhun E; Lim M; Mehta MP; Mellinghoff IK; Minniti G; Nathanson D; Platten M; Preusser M; Roth P; Sanson M; Schiff D; Short SC; Taphoorn MJB; Tonn JC; Tsang J; Verhaak RGW; von Deimling A; Wick W; Zadeh G; Reardon DA; Aldape KD; van den Bent MJ
Neuro Oncol; 2020 Aug; 22(8):1073-1113. PubMed ID: 32328653
[TBL] [Abstract][Full Text] [Related]
13. Pathway inhibition: emerging molecular targets for treating glioblastoma.
Wick W; Weller M; Weiler M; Batchelor T; Yung AW; Platten M
Neuro Oncol; 2011 Jun; 13(6):566-79. PubMed ID: 21636705
[TBL] [Abstract][Full Text] [Related]
14. Disease Assessments in Patients with Glioblastoma.
Phillips KA; Kamson DO; Schiff D
Curr Oncol Rep; 2023 Sep; 25(9):1057-1069. PubMed ID: 37470973
[TBL] [Abstract][Full Text] [Related]
15. A Review of Newly Diagnosed Glioblastoma.
Oronsky B; Reid TR; Oronsky A; Sandhu N; Knox SJ
Front Oncol; 2020; 10():574012. PubMed ID: 33614476
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.
Weenink B; French PJ; Sillevis Smitt PAE; Debets R; Geurts M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32235752
[TBL] [Abstract][Full Text] [Related]
17. Nonsurgical treatment of recurrent glioblastoma.
Gallego O
Curr Oncol; 2015 Aug; 22(4):e273-81. PubMed ID: 26300678
[TBL] [Abstract][Full Text] [Related]
18. A troublesome burden, the amplification of EGFR in glioblastoma!
Lobbous M; Nabors LB
Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420
[No Abstract] [Full Text] [Related]
19. Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials.
Rahman R; Ventz S; Redd R; Cloughesy T; Alexander BM; Wen PY; Trippa L
Clin Cancer Res; 2023 Jun; 29(12):2194-2198. PubMed ID: 36939557
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
